Literature DB >> 20802513

Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition.

T-H Chen1, P-C Chan, C-L Chen, H-C Chen.   

Abstract

Focal adhesion kinase (FAK) has a crucial role in integration of signals from integrins and growth factor receptors. In this study, we demonstrate that growth factor receptors including hepatocyte growth factor receptor Met, epidermal growth factor receptor, and platelet-derived growth factor receptor directly phosphorylate FAK on Tyr194 in the FERM domain (band 4.1 and ezrin/radixin/moesin homology domain). Upon binding to Met or phosphoinositides, FAK may undergo conformational changes, which renders Tyr194 accessible for phosphorylation. Substitution of Tyr194 with Phe significantly suppresses the activation of FAK by Met. In contrast, substitution of Tyr194 with Glu (Y194E substitution) leads to constitutive activation of FAK. The phosphorylation of FAK on Tyr194 may cause conformational changes in the FERM domain, which disrupts the intramolecular inhibitory interaction between the FERM and kinase domains of FAK. Moreover, substitution of the basic residues in the (216)KAKTLRK(222) patch in the FERM domain with Ala antagonizes the effect of the Y194E substitution on FAK activation, thus suggesting that the interactions between the phosphorylated Tyr194 and the basic resides in the (216)KAKTLRK(222) patch may allow FAK to be activated through relief of its autoinhibition. Collectively, this study provides the first example to explain how FAK is activated by receptor tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802513     DOI: 10.1038/onc.2010.398

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  VEGF-induced vascular permeability is mediated by FAK.

Authors:  Xiao Lei Chen; Ju-Ock Nam; Christine Jean; Christine Lawson; Colin T Walsh; Erik Goka; Ssang-Taek Lim; Alok Tomar; Isabelle Tancioni; Sean Uryu; Jun-Lin Guan; Lisette M Acevedo; Sara M Weis; David A Cheresh; David D Schlaepfer
Journal:  Dev Cell       Date:  2012-01-17       Impact factor: 12.270

Review 2.  Manipulation of Focal Adhesion Signaling by Pathogenic Microbes.

Authors:  Korinn N Murphy; Amanda J Brinkworth
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

3.  Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.

Authors:  Deniz A Ucar; Andrew T Magis; Di-Hua He; Nicholas J Lawrence; Said M Sebti; Elena Kurenova; Maria Zajac-Kaye; Jianliang Zhang; Steven N Hochwald
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

Review 4.  Focal adhesion kinase signaling in unexpected places.

Authors:  Elizabeth G Kleinschmidt; David D Schlaepfer
Journal:  Curr Opin Cell Biol       Date:  2017-02-16       Impact factor: 8.382

5.  Addressing the Functional Determinants of FAK during Ciliogenesis in Multiciliated Cells.

Authors:  Ioanna Antoniades; Panayiota Stylianou; Neophytos Christodoulou; Paris A Skourides
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

Review 6.  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.

Authors:  Duangmani Thanapprapasr; Wei Hu; Anil K Sood; Robert L Coleman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

Review 8.  Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Authors:  William G Cance; Elena Kurenova; Timothy Marlowe; Vita Golubovskaya
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

9.  Tetraspan TM4SF5-dependent direct activation of FAK and metastatic potential of hepatocarcinoma cells.

Authors:  Oisun Jung; Suyong Choi; Sun-Bok Jang; Sin-Ae Lee; Ssang-Taek Lim; Yoon-Ju Choi; Hye-Jin Kim; Do-Hee Kim; Tae Kyoung Kwak; Hyeonjung Kim; Minkyung Kang; Mi-Sook Lee; Sook Young Park; Jihye Ryu; Doyoung Jeong; Hae-Kap Cheong; Hyun Jeong Kim; Ki Hun Park; Bong-Jin Lee; David D Schlaepfer; Jung Weon Lee
Journal:  J Cell Sci       Date:  2012-10-17       Impact factor: 5.285

Review 10.  Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Authors:  Aik-Choon Tan; Simon Vyse; Paul H Huang
Journal:  Drug Discov Today       Date:  2016-07-21       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.